Novel antibiotic treatment for skin and soft tissue infection

Current Opinion in Infectious Diseases

Volumn 27, Issue 2, 2014, Pages 116-124

  Dryden, Matthew S ^a  

^a BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

antibiotics; multidrug resistance; skin and soft tissue infection

Indexed keywords

ANTIBIOTIC AGENT; AVAROFLOXACIN; AVIBACTAM; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTOBIPROLE; CEFTOLOZANE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DELAFLOXACIN; FINAFLOXACIN; GLYCYLCYCLINE DERIVATIVE; ICLAPRIM; LINEZOLID; LIPOPEPTIDE; MOXIFLOXACIN; NADIFLOXACIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RADEZOLID; TAZOBACTAM; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CHEMICAL STRUCTURE; COMMUNICABLE DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SKIN STRUCTURE; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEADY STATE; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MICROBIAL; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84896722688     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000050     Document Type: Review

References (95)

1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
2. Dryden MS, Cooke J, Davey P. Antibiotic stewardship: more education and regulation not more availability. J Antimircob Chemother 2009; 64: 885-888.
3. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39:283-294.
4. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177.
5. Opal SM, Calandra T. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients. JAMA 2009; 302:2367-2368.
6. Chief Medical Officer's Report 2011. https://www.gov.uk/government/ publications/chief-medical-officer-annual-report-volume-2. [Accessed 10 December 2013]
7. Infectious Diseases Society of America. The 10 ×'20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50:1081-1083.
8. Dryden MS. Complicated skin and soft tissue infections caused by MRSA: epidemiology, risk factors and presentation. Surg Infect (Larchmt) 2008; 9 (Suppl 1):S3-S10.
9. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents 2009; 33 (S3):S2-S7.
10. Di Nubile MJ, Lipsky BA. Complicated infections of the skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 (Suppl 2):ii37-ii50.
11. Mejía C, Zurita J, Guzmán-Blanco M. Epidemiology and surveillance of methicillin-resistant Staphlococcus aureus in Latin America. Braz J Infect Dis 2010; 14 (Suppl 2):S79-86.
12. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-885.
13. Dryden M, Andrasevic A, Bassetti M, et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010; 16 (suppl 1):3-30.
14. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl 3):iii35-iii44.
15. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-292.
16. Stevens DL, Bisno AL, Chambers H, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-1406.
17. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 (Suppl S1):i3-i17.
18. Esposito S, BassettiM, Borre' S, et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother 2011; 23:251-262.
19. Awad SS, Elhabash SI, Lee L, et al. Increasing incidence of methicillinresistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg 2007; 194:606-610.
20. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-1705.
21. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:2628-2630.
22. Hyun DY, Mason EO, Forbes A, et al. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009; 28:57-59.
23. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-3413.
24. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-650.
25. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl 5):S341-S353.
26. Falcone M, Russo A, Pompeo ME, et al. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. Int J Antimicrob Agents 2012; 39:64-68.
27. Itani KM, Biswas P, Reisman A, et al. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillinresistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther 2012; 34:1667-1673.
28. Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2012; 199:804-816.
29. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53:335-344.
30. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-1415.
31. Belley A, McKay GA, Beaulieu S, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin resistant enterococci to effect bacterial cell killing. Antimicrob Agents Chemother 2010; 54:5369-5371.
32. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012; 54 (Suppl 3):S214-S219.
33. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63:1191-1199.
34. Arhin FF, Draghi DC, Pillar CM, et al. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother 2009; 11:4762-4771.
35. Arias CA, Mendes RE, Stilwell MG, et al. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012; 54 (Suppl 3):S233-S238.
36. Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012; 54 (Suppl 3):S203-S213.
37. Dunbar LM, Milata J, McClure T, Wasilewski MM, SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011; 55:3476-3484.
38. Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012; 54 (Suppl 3):S220-S228.
39. Belley A, Arhin FF, Sarmiento I, et al. Pharmacodynamics of a simulated single 1200mg dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2013; 57:205-211.
40. Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009; 53:4422-4428.
41. Food and Drug Administration. 2010. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment (DRAFT GUIDANCE). Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
42. European Medicines Agency Committee for Medicinal Products for Human Use. 2011. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. London, UK: Committee for Medicinal Products for Human Use.
43. Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 2012; 54 (Suppl 3):S239-S243.
44. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490.
45. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-2266.
46. Sharpe JN, Shively EH, Polk HC, et al. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSAcomplicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189:425-428.
47. Lipsky BA, Itani K, Norden C, et al. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38:17-24.
48. Dryden M, Saeed K, Townsend R, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother 2012; 67:2289-2296.
49. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or b-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:53-66.
50. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011; 66:iv7-iv15.
51. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843-1845.
52. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of 14C linezolid to healthy human subjects. Drug Metab Dispos 2001; 29:1136-1145.
53. Welshman IR, Stalker DJ, Wajsczuk CP. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Anti-Infect Drugs Chemother 1998; 16 (Suppl 1):54.
54. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of co-administration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001; 41:563-572.
55. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract]. In: Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Washington, DC: American Society for Microbiology; 2007. Abstr. A-115, p. 23.
56. Sisson TL, Jungbluth GL, Hopkins NK. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999; 39:1277-1282.
57. Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008; 64:1093-1100.
58. Traunmuller F, Schintler MV, Spende S, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 2010; 36: 84-86.
59. Gray A, Dryden M, Charos A. Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother 2012; 67:2297-2302.
60. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-4447.
61. Lawrence L, Danese P, DeVito J, et al. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother 2008; 52:1653-1662.
62. Bien P, Prokocimer P, Munoz KA, et al. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects [abstract]. In: 50th Intersci. Confer. Antimicrob. Agents Chemother. 12-15 September 2010, Boston, MA. Poster A1-103.
63. Flanagan S, Minassian SL, Fang E, et al. Lack of MAO inhibitory by tedizolid phosphate in clinical and nonclinical studies [abstract]. In: 52nd Intersci. Confer. Antimicrob. Agents Chemother. 9-12 September, San Francisco. Poster A-1295a.
64. Shawn KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the pro-drug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-4447.
65. Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. Antimicrob Agents and Chemother 2009; 63:713-715.
66. Lepak JA, Marchillo K, Pichereau S, et al. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. J Antimicrob Chemother 2012; 56:5916-5922.
67. Prokocimer P, Anda De C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections, the ESTABLISH- 1 randomized trial. JAMA 2013; 309:559-569.
68. Fang E, Anda De C, Das A, Prokocimer P. Efficacy and safety results from the ESTABLISH-2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid [abstract]. In: 23rd European Society of Clinical Microbiology and Infectious Disease (ESCMID), 27-30 April 2013, Berlin, Germany. Poster LB2964.
69. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-tructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41:S341-S353.
70. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 (Suppl 1):i17-i28.
71. Namdari H, Tan TY, Dowzicky MJ. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009. Int J Infect Dis 2012; 16:e60-e66.
72. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med 2012; 79:57-66.
73. Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004- 2009). Int J Antimicrob Agents 2012; 39:115-123.
74. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (Suppl 5):S315-S332.
75. Dowzicky MJ, Chmelarova E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011; 37:562-566.
76. Stein GE, Smith CL, Missavage A. Tigecycline penetration into skin and soft tissue. Surg Infect (Larchmt) 2011; 12:465-467.
77. Montravers P, Bassetti M, Dupont H, et al. Efficacy of tigecycline for the treatment of complicated skin and soft tissue infections in real-life clinical practice from five European observational trials. J Antimicrob Chemother 2013; 68 (Suppl 2):ii15-ii24.
78. Gonzalez-Ruiz A, Hans Lehmkuhl A, Seaton RA, et al. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother 2011; 66:912-919.
79. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
80. Hawkey PM. Preclinical experience with daptomycin. J Antimicrob Chemother 2008; 62 (Suppl 3):iii7-ii14.
81. Barberán J, Fariñas MC. [Daptomycin in complicated skin and soft tissue infections]. Enferm Infecc Microbiol Clin 2012; 30 (Suppl 1):33-37.
82. Quist SR, Fierlbeck G, Seaton RA, et al. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents 2012; 39:90-91.
83. Woodcock KM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41:101-106.
84. Giordano P, Song J, Pertel P, et al. Sequential intravenous/PO moxifloxacin versus intravenous pipericillin-tazobactam followed by PO amoxicillin/clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26:357-365.
85. Gyssens IC, Dryden M, Kujath P, et al. Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of major abscess: results of the RELIEF study [abstract]. In: European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 2009. Poster 1786. European Society for Clinical Microbiology and Infectious Diseases.
86. Gyssens IC, Dryden M, Kujath P, et al. Efficacy of IV/PO moxifloxacin in the treatment of complicated skin and skin structure infections: results of the RELIEF study [abstract]. In: European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, 2009. Poster 1785. European Society for Clinical Microbiology and Infectious Diseases.
87. Schaper N, Dryden M, Kujath P, et al. Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin-clavulanate in the treatment of diabetic foot infections: results of the RELIEF study [abstract]. In: European Congress of Clinical Microbiology and Infectious Diseases, Vienna 2010. Poster 1550. European Society for Clinical Microbiology and Infectious Diseases.
88. Shopsin B, Zhao X, Kreiswirth BN, et al. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004; 24:32-34; iii44.
89. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intraabdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48:1012-1016.
90. Jacobs E, Dalhoff A, Korfmann G. Susceptibility pattern of bacterial isolates from hospitalised patients with respiratory tract infections (RTI), (MOXIAKTIV study). Int J Antimicrob Agents 2009; 33:52-57.
91. Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 ×'20 Progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-1694.
92. Hernandez PO, Lema S, Tyring SK, Mendoza N. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist 2012; 5:23-35.
93. Friedland HD, O'Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:2231-2236.
94. Goodman J, Martin SI. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 2012; 8:149-156.
95. Garrison MW, Kawamura NM, Wen MM. Cetaroline fosamil; a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti Infect Ther 2012; 10:1087-1103.